Premier Stocks League

Eli Lilly Stock Is Not Done Growing Yet, But It's Due For Compression (Rating Downgrade) 🔗

Eli Lilly (LLY) stock looks attractive vs. overextended semiconductors, with strong Q2 growth and reasonable PEG. See here for more details.

Lilly Launches Foundayo in the UK as NICE Review Continues 🔗

Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral tre...

Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible? 🔗

Testing for Alzheimer’s-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access. Roch...

Jim Cramer flagged one stock quietly concentrating portfolios 🔗

The portfolio looks diversified. Cramer says look again

Dividend Champion, Contender, And Challenger Highlights: Week September 6 🔗

Explore this week’s dividend updates for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend and pay...

Whale's Insight: Rate Hike? 6 Reasons The Fed Holds In September 🔗

Bitcoin is trading on hike odds, falling from 81K to 76K on Warsh's hawkish tone and rebounding to 82.2K on Waller's dovish turn. Read more ...

Novo Nordisk (CPSE:NOVO B) Stock Looks Below Fair Value But Faces Earnings Doubts 🔗

Novo Nordisk stock has fallen sharply over the past three years, yet valuation checks still lean toward the shares looking cheap rather than stretched...

Was JNJ Stock Rally Actually Its Own? 🔗

Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The bios...

Lilly looks beyond obesity with $2.88B autoimmune buyout 🔗

The maker of Mounjaro and Zepbound just signed its 13th deal of the year.

Lilly (LLY) Down 2.7% Since Last Earnings Report: Can It Rebound? 🔗

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Deal Dispatch: Nvidia Buys Hugging Face for $12.9 Billion, Barilla Acquires Goodles, Park Place Partners Bankruptcy 🔗

Major M&A deals include Flex buys EPC Power for $4.4 Billion, KKR acquires A1 Garage Door, Starman Optical Buys GoPro.

AMGN's MariTide: Can Convenience Drive its Obesity Market Share? 🔗

Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifi...

This week in charts: China deals, stock flatlines and Lilly’s M&A spree 🔗

Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly...

Superluminal Medicines secures $60m to advance rare obesity therapy 🔗

Superluminal Medicines will use the proceeds to advance its MC4R agonist candidate into Phase I trials by 2026.

12 Top Press Releases from August 🔗

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumer...

Lilly's African Mounjaro Push Starts at 1.25% of Quarterly Sales 🔗

Aspen's target is financially small today but creates an early map for GLP-1 expansion across Africa.

Great News for Eli Lilly Stock Investors 🔗

There is no end in sight for the company's incredible momentum.

Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense 🔗

Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.

Is Merck Stock Pricing In A Post-Keytruda Future Too Soon? 🔗

Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.

What Does Eli Lilly (LLY) Gain From Its $2.88 Billion Immunology Deal? 🔗

Eli Lilly (NYSE: LLY) agreed to acquire Merida Biosciences in a deal valued at up to US$2.88b to expand its immunology pipeline. The transaction bring...

ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care? 🔗

A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-re...

Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided? 🔗

Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 s...

Pfizer's Pipeline Strategy Centers on Obesity and Oncology 🔗

PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.

Superluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the Clinic 🔗

Superluminal Medicines, a biotechnology company integrating AI/ML, protein dynamics and structural biology to rapidly unlock some of the most challeng...

Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress 🔗

Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa...

Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President 🔗

President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S...

Eli Lilly Just Announced a Major Acquisition. Here's What It Means. 🔗

The drug giant added to its immunotherapy portfolio.

HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss 🔗

HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.

How Did Merck Stock Beat The Market With Slowing Sales? 🔗

Before the eighty-five percent surge, the company's pipeline story was getting louder just as its revenue trajectory was getting quieter.

Lilly’s Record Stock Price Is Hiding an Even Bigger Opportunity 🔗

Eli Lilly just delivered one of the biggest quarters in Big Pharma history, yet the stock sits well below its 52-week high. A closer look at the pipel...

AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks 🔗

AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay inv...

Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s? 🔗

Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster car...

Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity 🔗

Eli Lilly's $2.875 billion Merida Biosciences deal expands its immunology pipeline, as strong GLP-1 growth continues while LLY shares trail the b...

Peptide innovator says the drug class is due for a rethink 🔗

Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption.

Top 25 High-Growth Dividend Stocks For September 2026 🔗

The September 2026 Top 25 High-Growth Dividend Stocks list targets quality companies trading below intrinsic value with strong long-term return potent...

Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications 🔗

FDA warns of risks from unapproved compounded GLP-1 drugs including semaglutide and tirzepatide amid rising adverse event reports.

Tracking Jeremy Grantham's GMO Capital Portfolio - Q2 2026 Update 🔗

GMO’s 13F portfolio jumps to ~$44B. See top holdings, key buys/sells, and rebalancing across tech, healthcare & financials—read the upda...

This New Zepbound Study Could Be Great News for Eli Lilly Investors 🔗

The high-flying healthcare leader looks unstoppable right now.

Novo Nordisk Trades Nearly 58% Below GF Value as Wegovy Pill Launches in Germany 🔗

Germany becomes the first EU market for oral Wegovy, testing Novo's early lead as Eli Lilly expands.

Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal 🔗

LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.

Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet 🔗

Employer coverage of GLP-1 drugs is collapsing heading into 2027, but the FDA just gave Eli Lilly a specific piece of ammunition that could change the...

Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference 🔗

Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, e...

GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit? 🔗

GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.

FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients 🔗

https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs 🔗

Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most...

Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal 🔗

Merida's lead programme, MER511, is in Phase I development for Graves' disease and thyroid eye disease (TED).

SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’ 🔗

Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.

Lilly's $2.88 Billion Immunology Deal Starts in Phase 1 🔗

The milestone-heavy purchase adds a broad scientific platform, but its lead medicine remains at the earliest clinical stage.

Eli Lilly (LLY) Makes a $2.88 Billion Autoimmune Bet. What Could Go Right or Wrong? 🔗

Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront paymen...

Chris Benecchi Named Inventiva’s New Chief Operating Officer 🔗

By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive ...

Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors. 🔗

Hardly for the first time recently, the company is making a pricey acquisition.

Sector Update: Healthcare Stocks Decline Late Afternoon 🔗

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% a

Lilly Is Bigger Than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense. 🔗

Eli Lilly agrees to acquire Merida Biosciences, the developer of autoimmune drugs, marking the latest move to bolster its portfolio through strategic ...

A $2.88 Billion Reason Why Eli Lilly Stock Is in Focus Today 🔗

Eli Lilly announced a $2.88 billion acquisition of Merida Biosciences. Here’s what it means for LLY shares.

Nvidia’s Scarcity Runs Out in Five Years: ‘A Chip Designed by OpenAI, by AI’ 🔗

OpenAI just built an AI-designed chip that already beats Nvidia's best in early tests, and one macro investor has pinpointed exactly when Nvidia&...

This Popular Healthcare ETF Is Diluting Your Dividend Income 🔗

XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors ...

Eli Lilly CEO Says $25B Deal Spree Is About Building Growth Beyond Obesity Into 2030s — ‘Not All These Bets Will Pay Off’ 🔗

In an interview with CNBC, CEO David Ricks said the company’s long-term strategy includes making its obesity franchise more durable and investing in...

Eli Lilly (LLY) Stock May Be 30% Undervalued Despite Fresh FDA Approval 🔗

Eli Lilly stock has delivered very strong gains over the past five years. Current checks give a mixed read on valuation, with the Discounted Cash Flow...

Eli Lilly Stock Falls After Pharma Giant Unveils $2.9 Billion Acquisition 🔗

Eli Lilly Stock Slides as Pharma Giant Strikes $2.9 Billion Merida Deal

AtaiBeckley Says Hart-Scott-Rodino Waiting Period For Merger With Eli Lilly Expired On Aug 28, 2026; UK Competition Authority Has No Further Questions On Merger As Of August 21, 2026 🔗

As previously disclosed, AtaiBeckley Inc. (the "Company") entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the...

Eli Lilly's Next $2.9 Billion Bet Is Not About Obesity 🔗

The Merida acquisition adds an early-stage autoimmune platform as Lilly broadens its pipeline.

Eli Lilly to buy Merida Biosciences for up to $2.88B, expanding immunology pipeline 🔗

Eli Lilly and Co (NYSE:LLY) said on Monday it will acquire privately held Merida Biosciences for up to $2.88 billion in cash, part of a deal-making pu...

Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know 🔗

Stocks making the biggest moves midday: PG&E, Edison International, Apple, Howmet Aerospace, Eli Lilly & more 🔗

These are some of the stocks posting the largest moves midday.

Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs 🔗

Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more a...

G20 meeting live updates: Bessent, Warsh kick off summit with growth-focused remarks 🔗

This is CNBC's live blog of the U.S. G20 finance ministerial in Asheville, North Carolina. Please check back for updates.